CU20170123A7 - Heterociclilmetil-tienouracilo como antagonistas del receptor de adenosina-a2b - Google Patents
Heterociclilmetil-tienouracilo como antagonistas del receptor de adenosina-a2bInfo
- Publication number
- CU20170123A7 CU20170123A7 CUP2017000123A CU20170123A CU20170123A7 CU 20170123 A7 CU20170123 A7 CU 20170123A7 CU P2017000123 A CUP2017000123 A CU P2017000123A CU 20170123 A CU20170123 A CU 20170123A CU 20170123 A7 CU20170123 A7 CU 20170123A7
- Authority
- CU
- Cuba
- Prior art keywords
- adenosine receptor
- tienouracilo
- heterociclilmetil
- antagonists
- tienouracil
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Cardiology (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Transplantation (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
<p>La presente solicitud se refiere a derivados novedosos de tieno[2,3-d]pirimidina-2,4-diona(¨tienouracilo¨) como agonistas del recpetor de adenosina A2b</p> <p>ESPACIO PARA LA FÓRMULA</p> <p>que presentan un tipo particular de sustituyente (azaheterociclil)metilo, y a procesos para la preparación de los mismos, y a medicamentos que contiene a los mismos por sí solos o en combinaciones.</p>
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP15161165 | 2015-03-26 | ||
EP15174566 | 2015-06-30 | ||
EP15184732 | 2015-09-10 | ||
PCT/EP2016/056106 WO2016150901A1 (de) | 2015-03-26 | 2016-03-21 | Heterocyclylmethyl-thienouracile als antagonisten des adenosin-a2b-rezeptors |
Publications (1)
Publication Number | Publication Date |
---|---|
CU20170123A7 true CU20170123A7 (es) | 2018-02-08 |
Family
ID=55586319
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CUP2017000123A CU20170123A7 (es) | 2015-03-26 | 2016-03-21 | Heterociclilmetil-tienouracilo como antagonistas del receptor de adenosina-a2b |
Country Status (24)
Country | Link |
---|---|
US (1) | US10428083B2 (es) |
EP (1) | EP3274352B1 (es) |
JP (1) | JP2018509443A (es) |
KR (1) | KR20170131540A (es) |
CN (1) | CN107646035A (es) |
AU (1) | AU2016236272A1 (es) |
BR (1) | BR112017020317A2 (es) |
CA (1) | CA2980646A1 (es) |
CL (1) | CL2017002390A1 (es) |
CO (1) | CO2017009656A2 (es) |
CR (1) | CR20170437A (es) |
CU (1) | CU20170123A7 (es) |
DO (1) | DOP2017000212A (es) |
EA (1) | EA201792134A1 (es) |
EC (1) | ECSP17064196A (es) |
IL (1) | IL254476A0 (es) |
MX (1) | MX2017012308A (es) |
PE (1) | PE20180116A1 (es) |
PH (1) | PH12017501758A1 (es) |
SG (1) | SG11201707577VA (es) |
TN (1) | TN2017000415A1 (es) |
TW (1) | TW201700480A (es) |
UY (1) | UY36586A (es) |
WO (1) | WO2016150901A1 (es) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018041771A1 (de) | 2016-09-02 | 2018-03-08 | Bayer Pharma Aktiengesellschaft | (1-methylcyclopropyl)methyl-substituierte thienouracile und ihre verwendung |
JP2019529452A (ja) * | 2016-09-23 | 2019-10-17 | バイエル・アクチエンゲゼルシヤフト | N3−環状置換チエノウラシルおよびその使用 |
JP6999112B2 (ja) * | 2016-11-29 | 2022-02-04 | 国立研究開発法人産業技術総合研究所 | 2,5-ビス(アミノメチル)フラン二ハロゲン化水素塩及びその製造方法並びに2,5-ビス(アミノメチル)フランの製造方法 |
AU2019367187A1 (en) | 2018-10-24 | 2021-03-25 | Leadxpro Ag | Functionalized aminotriazines |
WO2020146795A1 (en) | 2019-01-11 | 2020-07-16 | Omeros Corporation | Methods and compositions for treating cancer |
WO2020172338A1 (en) * | 2019-02-19 | 2020-08-27 | Whitehead Institute For Biomedical Research | Methods and agents for modulating mitochondrial nad levels |
CN112625050B (zh) | 2019-07-30 | 2021-10-01 | 杭州阿诺生物医药科技有限公司 | 一种a2a和/或a2b受体抑制剂的制备方法 |
CN112028891B (zh) | 2019-07-30 | 2022-07-05 | 厦门宝太生物科技股份有限公司 | 腺苷受体拮抗剂 |
CN111875615A (zh) * | 2020-07-15 | 2020-11-03 | 济南大学 | 一种甲氧基苄脲类化合物及其用途 |
WO2022053651A2 (en) | 2020-09-10 | 2022-03-17 | Precirix N.V. | Antibody fragment against fap |
WO2023203135A1 (en) | 2022-04-22 | 2023-10-26 | Precirix N.V. | Improved radiolabelled antibody |
WO2023213801A1 (en) | 2022-05-02 | 2023-11-09 | Precirix N.V. | Pre-targeting |
Family Cites Families (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2036171A1 (es) | 1970-07-21 | 1972-01-27 | ||
US6140325A (en) | 1993-08-19 | 2000-10-31 | Takeda Chemical Industries, Ltd. | Thienopyrimidine derivatives, their production and use |
TW276256B (es) * | 1993-08-26 | 1996-05-21 | Takeda Pharm Industry Co Ltd | |
DE69839392T2 (de) | 1997-02-26 | 2009-05-20 | Hokko Chemical Industry Co. Ltd. | In 1-stellung substituierte 4-carbamoyl-1,2,4-triazol-5-on-derivate und herbizide |
SE9702001D0 (sv) | 1997-05-28 | 1997-05-28 | Astra Pharma Prod | Novel compounds |
DE19834044A1 (de) | 1998-07-29 | 2000-02-03 | Bayer Ag | Neue substituierte Pyrazolderivate |
DE19834047A1 (de) | 1998-07-29 | 2000-02-03 | Bayer Ag | Substituierte Pyrazolderivate |
WO2000012514A1 (en) * | 1998-08-28 | 2000-03-09 | Astrazeneca Ab | Novel compounds |
MXPA01010143A (es) | 1999-04-09 | 2003-07-14 | Cell Therapeutics Inc | Derivados de xantina y analogos como inhibidores de transmision de senales celulares. |
DE19943636A1 (de) | 1999-09-13 | 2001-03-15 | Bayer Ag | Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften |
DE19943639A1 (de) | 1999-09-13 | 2001-03-15 | Bayer Ag | Dicarbonsäurederivate mit neuartigen pharmazeutischen Eigenschaften |
DE19943634A1 (de) | 1999-09-13 | 2001-04-12 | Bayer Ag | Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften |
DE19943635A1 (de) | 1999-09-13 | 2001-03-15 | Bayer Ag | Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften |
JP2003531910A (ja) * | 2000-05-04 | 2003-10-28 | アストラゼネカ アクチボラグ | チエノ[2,3−d]ピリミジンジオン類とそれらの医薬品としての使用 |
GB2363377B (en) * | 2000-06-14 | 2004-06-09 | Astrazeneca Ab | Novel thieno[2,3-d]pyrimidinediones and therapeutic uses thereof |
AR031176A1 (es) | 2000-11-22 | 2003-09-10 | Bayer Ag | Nuevos derivados de pirazolpiridina sustituidos con piridina |
MXPA03004926A (es) | 2001-02-14 | 2005-02-14 | Warner Lambert Co | Inhibidores de metaloproteinasas de matriz basados en pirimidinonas fusionadas. |
DE10110750A1 (de) | 2001-03-07 | 2002-09-12 | Bayer Ag | Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften |
DE10110749A1 (de) | 2001-03-07 | 2002-09-12 | Bayer Ag | Substituierte Aminodicarbonsäurederivate |
DE10220570A1 (de) | 2002-05-08 | 2003-11-20 | Bayer Ag | Carbamat-substituierte Pyrazolopyridine |
AU2003253165A1 (en) | 2002-08-13 | 2004-02-25 | Warner-Lambert Company Llc | Pyrimidine fused bicyclic metalloproteinase inhibitors |
US6890923B2 (en) * | 2002-12-16 | 2005-05-10 | Astrazeneca Ab | Compounds |
SE0300119D0 (sv) * | 2003-01-17 | 2003-01-17 | Astrazeneca Ab | Novel compounds |
MXPA05007495A (es) * | 2003-01-17 | 2005-09-21 | Astrazeneca Ab | Tienopiridazinonas y su uso en la modulacion de enfermedades autoinmunes. |
WO2006029115A2 (en) | 2004-09-02 | 2006-03-16 | 3M Innovative Properties Company | 2-amino 1h imidazo ring systems and methods |
WO2007103776A2 (en) | 2006-03-02 | 2007-09-13 | Cv Therapeutics, Inc. | A2a adenosine receptor antagonists |
CA2670788A1 (en) * | 2006-12-01 | 2008-06-12 | Cv Therapeutics, Inc. | A2a adenosine receptor antagonists |
GB0718432D0 (en) * | 2007-09-21 | 2007-10-31 | Vernalis R&D Ltd | New chemical compounds |
WO2010089580A1 (en) * | 2009-02-06 | 2010-08-12 | Astrazeneca Ab | Use of a mct1 inhibitor in the treatment of cancers expressing mct1 over mct4 |
DE102010021637A1 (de) | 2010-05-26 | 2011-12-01 | Bayer Schering Pharma Aktiengesellschaft | Substituierte 5-Fluor-1H-Pyrazolopyridine und ihre Verwendung |
EA201390060A1 (ru) | 2010-07-09 | 2013-07-30 | Байер Интеллектуэль Проперти Гмбх | Аннелированные пиримидины и триазины и их применение для лечения и/или профилактики сердечно-сосудистых заболеваний |
DE102010040233A1 (de) | 2010-09-03 | 2012-03-08 | Bayer Schering Pharma Aktiengesellschaft | Bicyclische Aza-Heterocyclen und ihre Verwendung |
SG188985A1 (en) | 2010-09-17 | 2013-05-31 | Array Biopharma Inc | Piperidinyl-substituted lactams as gpr119 modulators |
DE102010043379A1 (de) | 2010-11-04 | 2012-05-10 | Bayer Schering Pharma Aktiengesellschaft | Substituierte 6-Fluor-1H-Pyrazolo[4,3-b]pyridine und ihre Verwendung |
WO2012166700A2 (en) * | 2011-05-29 | 2012-12-06 | Lisanti Michael P | Molecular profiling of a lethal tumor microenvironment |
SI2776038T1 (en) | 2011-11-11 | 2018-06-29 | Gilead Apollo, Llc | ACC INHIBITORS AND THEIR USE |
WO2013112881A1 (en) * | 2012-01-27 | 2013-08-01 | Thomas Jefferson University | Mct protein inhibitor-related prognostic and therapeutic methods |
US20130287791A1 (en) * | 2012-04-25 | 2013-10-31 | C. Wilson Xu | Modulation of histone h2b monoubiquitination and treatment of cancer |
CA2911818A1 (en) | 2013-05-10 | 2014-11-13 | Nimbus Apollo, Inc. | Acc inhibitors and uses thereof |
JP6417401B2 (ja) | 2013-05-10 | 2018-11-07 | ギリアド アポロ, エルエルシー | Acc阻害剤及びその使用 |
TN2016000121A1 (en) * | 2013-10-07 | 2017-10-06 | Bayer Pharma AG | Cyclic thienouracil-carboxamides and use thereof |
-
2016
- 2016-03-14 UY UY0001036586A patent/UY36586A/es not_active Application Discontinuation
- 2016-03-21 MX MX2017012308A patent/MX2017012308A/es unknown
- 2016-03-21 EA EA201792134A patent/EA201792134A1/ru unknown
- 2016-03-21 WO PCT/EP2016/056106 patent/WO2016150901A1/de active Application Filing
- 2016-03-21 SG SG11201707577VA patent/SG11201707577VA/en unknown
- 2016-03-21 KR KR1020177030414A patent/KR20170131540A/ko unknown
- 2016-03-21 PE PE2017001562A patent/PE20180116A1/es not_active Application Discontinuation
- 2016-03-21 CU CUP2017000123A patent/CU20170123A7/es unknown
- 2016-03-21 EP EP16710764.8A patent/EP3274352B1/de active Active
- 2016-03-21 CN CN201680029026.6A patent/CN107646035A/zh active Pending
- 2016-03-21 US US15/560,265 patent/US10428083B2/en not_active Expired - Fee Related
- 2016-03-21 AU AU2016236272A patent/AU2016236272A1/en not_active Abandoned
- 2016-03-21 JP JP2017549662A patent/JP2018509443A/ja active Pending
- 2016-03-21 CR CR20170437A patent/CR20170437A/es unknown
- 2016-03-21 CA CA2980646A patent/CA2980646A1/en not_active Abandoned
- 2016-03-21 BR BR112017020317-0A patent/BR112017020317A2/pt not_active Application Discontinuation
- 2016-03-21 TN TNP/2017/000415A patent/TN2017000415A1/en unknown
- 2016-03-24 TW TW105109156A patent/TW201700480A/zh unknown
-
2017
- 2017-09-13 IL IL254476A patent/IL254476A0/en unknown
- 2017-09-19 DO DO2017000212A patent/DOP2017000212A/es unknown
- 2017-09-22 CL CL2017002390A patent/CL2017002390A1/es unknown
- 2017-09-25 CO CONC2017/0009656A patent/CO2017009656A2/es unknown
- 2017-09-25 PH PH12017501758A patent/PH12017501758A1/en unknown
- 2017-09-26 EC ECIEPI201764196A patent/ECSP17064196A/es unknown
Also Published As
Publication number | Publication date |
---|---|
CL2017002390A1 (es) | 2018-05-11 |
WO2016150901A1 (de) | 2016-09-29 |
PH12017501758A1 (en) | 2018-04-11 |
CN107646035A (zh) | 2018-01-30 |
CR20170437A (es) | 2017-11-14 |
EP3274352B1 (de) | 2019-01-02 |
EA201792134A1 (ru) | 2018-03-30 |
JP2018509443A (ja) | 2018-04-05 |
TW201700480A (zh) | 2017-01-01 |
MX2017012308A (es) | 2018-01-26 |
BR112017020317A2 (pt) | 2018-06-05 |
US10428083B2 (en) | 2019-10-01 |
CA2980646A1 (en) | 2016-09-29 |
EP3274352A1 (de) | 2018-01-31 |
TN2017000415A1 (en) | 2019-01-16 |
DOP2017000212A (es) | 2017-11-15 |
AU2016236272A1 (en) | 2017-10-12 |
IL254476A0 (en) | 2017-11-30 |
PE20180116A1 (es) | 2018-01-18 |
UY36586A (es) | 2016-10-31 |
US20180065981A1 (en) | 2018-03-08 |
ECSP17064196A (es) | 2017-10-31 |
CO2017009656A2 (es) | 2018-01-16 |
KR20170131540A (ko) | 2017-11-29 |
SG11201707577VA (en) | 2017-10-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CU20170123A7 (es) | Heterociclilmetil-tienouracilo como antagonistas del receptor de adenosina-a2b | |
FR22C1006I2 (fr) | Derives de pyrrolo-[2,3-d]pyrimidine en tant qu'inhibiteurs des janus kinases (jak) | |
CO2017008403A2 (es) | Derivados de nucleósidos sustituidos útiles como agentes antineoplásicos | |
CU20170160A7 (es) | Derivadosde fenil-tieno(2,3-d)pirimidina- hidroxi-ésteres, un proceso para su preparación y composiciones farmacéuticas que lo contienen | |
NI201600144A (es) | Derivados de quinoxalina utiles como moduladores del fgfr cinasa | |
CR20160400A (es) | Derivados de nucleosido sustituidos con 4´-difluorometilo como inhibidores de la replicación de arn de la influenza | |
SI3379933T1 (sl) | Fungicidni sestavki, ki vsebujejo derivate 2,4-diokso-1,4-dihidrotieno (2,3-d)pirimidina | |
CR20150228A (es) | Inhibidores de la tirosina-quinasa de bruton | |
CL2015003686A1 (es) | Derivados de pirrolo[3,2-d]pirimidina para el tratamiento de infecciones víricas y otras enfermedades | |
CR20150263A (es) | Compuestos de pirrolopirimidina como inhibidores de quinasas | |
DOP2015000270A (es) | Potenciador de inhibidores del homólogo de zeste | |
CO7131375A2 (es) | Uracilos sustituidos bicíclicamente y uso de los mismos | |
CL2018002811A1 (es) | Derivados de aminotiazol útiles como agentes antivíricos. | |
EA201591939A1 (ru) | ПРОИЗВОДНЫЕ ПИРРОЛО[2,3-d]ПИРИМИДИНА В КАЧЕСТВЕ АГОНИСТОВ РЕЦЕПТОРА CB2 | |
ECSP15050386A (es) | FORMULACIONES ALTERNATIVAS PARA POLIPÉPTIDOS DE FUSIÓN TNFR: Fc | |
CU20160044A7 (es) | DERIVADOS DE 2,4 DIOXO-1,2,3,4-TETRAHIDROTIENO(2,3-d) PIRIMIDINA-6-CARBOXAMIDAS COMO ANTAGONISTAS DE RECEPTORES A2b DE ADENOSINA | |
RS55449B1 (sr) | Novi derivati pirimidina kao inhibitori fosfodiesteraze 10 (pde-10) | |
LV14851A (lv) | Triazolilpur&imacr;na atvasin&amacr;jumi k&amacr; adenoz&imacr;na un pur&imacr;na receptoru agonisti |